MedTrace Logo

Evaluation of Lovastatin in Severe Persistent Asthma

NCT00689806 · Status: WITHDRAWN · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL

Last updated 2013-06-21

No results posted yet for this study

Summary

This study has two purposes:

1. to determine whether lovastatin, a commonly used medication to lower cholesterol in the blood, can produce beneficial changes in airway inflammation and in the airway smooth muscle
2. to examine whether lovastatin will have favorable changes in asthma symptoms of patients with moderate or severe asthma.

Conditions

  • Severe Persistent Asthma

Interventions

DRUG

Lovastatin

Lovastatin 20 mg extended release (or placebo) by mouth once daily for weeks 1-4. Liver function test will be checked at week 4 follow up visit. If LFTs are not \> 3 times the upper limit of normal, then the subject will have the dose of extended release lovastatin increased to 60 mg once a day for weeks 4-12

DRUG

Placebo

Placebo by mouth once daily for weeks 1-4.

Sponsors & Collaborators

  • University of Chicago

    lead OTHER

Principal Investigators

  • Blanca Camoretti-Mercado, Ph.D. · University of Chicago

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00689806 on ClinicalTrials.gov